Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines
Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, Abou‐Alfa G. Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines. The Oncologist 2020, 26: e316-e326. PMID: 33021006, PMCID: PMC7873330, DOI: 10.1002/onco.13552.Peer-Reviewed Original ResearchConceptsSelective FGFR inhibitorsAdverse eventsDermatologic adverse eventsTyrosine kinaseFibroblast growth factor receptor tyrosine kinaseFGFR inhibitorsBladder cancerGrowth factor receptor tyrosine kinaseSkin eventsReceptor tyrosine kinasesPalmar-plantar erythrodysesthesia syndromeSelective fibroblast growth factor receptor (FGFR) inhibitorFibroblast growth factor receptor inhibitorManagement guidelinesGrowth factor receptor inhibitorsSkin adverse eventsTypical adverse eventsFrequent adverse eventsPossible adverse eventsEffective treatment strategiesBiological functionsEffective management plansQuality of lifeDermatologic eventsFGFR fusionsCutaneous immune-related adverse events to checkpoint inhibitors
Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics In Dermatology 2020, 38: 660-678. PMID: 33341200, DOI: 10.1016/j.clindermatol.2020.06.011.Peer-Reviewed Original ResearchConceptsAdverse reactionsCheckpoint inhibitorsImmune-related adverse reactionsCheckpoint inhibitor therapyCutaneous adverse eventsOngoing cancer treatmentPD-1 inhibitorsCTLA-4 inhibitorsImmune checkpoint inhibitorsCutaneous adverse reactionsPD-L1 inhibitorsDevelopment of immunotherapySuch adverse reactionsImmunomodulatory therapyTreatment interruptionAssociated morbidityPatient comorbiditiesAdverse eventsCutaneous toxicityInhibitor therapyImmune statusHematologic malignanciesEarly recognitionCancer treatmentManagement guidelines